Skip to main content
. 2012 Mar 21;7(3):e33682. doi: 10.1371/journal.pone.0033682

Table 7. Genotype-phenotype associations of the PTPN2 SNP rs2542151 in UC patients.

PTPN2 SNP rs2542151 TT (n = 226) TG (n = 80) GG (n = 12) PG ORG [95% CI]
Gender (n = 318)
Male 125 (55.3%) 36 (45.0%) 5 (41.7%) 8.03×10−2 1.54 [0.95–2.51]
Female 101 (44.7%) 44 (55.0%) 7 (58.3%)
Age at diagnosis (yrs) (n = 302)
Mean ± SD 29.45±14.60 27.95±14.13 25.08±15.54 0.253 1.34 [0.81–2.21]
Range 2–81 4–73 9–68
Age at diagnosis (n = 302)
< = 16 years (A1) (n = 59) 41 (19.1%) 16 (21.3%) 2 (16.7%) 0.926 0.97 [0.51–1.83] (A1 vs. A2)
17–40 years (A2) (n = 183) 126 (58.6%) 49 (65.3%) 8 (66.7%) 9.95×10−2 1.81 [0.89–3.67] (A2 vs. A3)
>40 years (A3) (n = 60) 48 (22.3%) 10 (13.3%) 2 (16.7%) 0.189 1.76 [0.76–4.07] (A1 vs. A3)
BMI (kg/m2) (n = 209)
Mean ± SD 23.92±4.74 23.87±3.83 23.67±4.71 0.995 1.00 [0.55–1.82]
Range 15–54 16–36 15–30
Location (n = 200)
Proctitis (E1) (n = 24) 15 (12.0%) 7 (10.6%) 2 (22.2%) 0.329 1.55 [0.64–3.70]
Left-sided UC (E2) (n = 96) 73 (58.4%) 20 (30.3%) 3 (33.3%) 0.184 0.68 [0.38–1.20]
Extensive UC (E3) (n = 80) 37 (29.6%) 39 (59.1%) 4 (44.4%) 0.473 1.22 [0.83–1.80]
Extra-intestinal manifestations (n = 191) no: 87 (64.4%) 33 (68.8%) 5 (62.5%) 0.652 0.86 [0.44–1.66]
yes:48 (35.6%) 15 (31.3%) 3 (37.5%)
Use of immuno-suppressive agents no: 50 (26.0%) 14 (20.9%) 2 (22.2%) 0.394 1.32 [0.70–2.50]
(n = 268) yes: 142 (74.0%) 53 (79.1%) 7 (77.8%)
Abscesses (n = 240) no: 160 (96.4%) 61 (93.8%) 7 (77.8%) 0.151 2.35 [0.73–7.56]
yes: 6 (3.6%) 4 (6.2%) 2 (22.2%)

PG: p-value for association comparing carriers of the G-allele to individuals homozygous for A. Association results for age at diagnosis and BMI are based on median split. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis tested: n = 12, resulting in a significance threshold of p<4.167×10−3).